MGX Metagenomi Inc.
- Stocks
- Healthcare
- NASDAQ: MGX
Price (delayed)
$2.26
Market cap
$84.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$95.72M
Relative Growth:
Rel. Growth:
37
Relative Strength:
Rel. Strength:
58
Relative Valuation:
Rel. Valuation:
19
Relative Profitability:
Rel. Profitability:
32
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set
Highlights
The debt has declined by 10% year-on-year and by 3.3% since the previous quarter
MGX's quick ratio is up by 9% year-on-year and by 9% since the previous quarter
Metagenomi's EPS has soared by 82% YoY but it has decreased by 12% from the previous quarter
The company's gross profit fell by 40% YoY and by 25% QoQ
The revenue has declined by 40% year-on-year and by 25% since the previous quarter
Key stats
What are the main financial stats of MGX
Market
Valuations
Earnings
Shares outstanding
37.53M
Market cap
$84.82M
Enterprise value
$95.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
2.49
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.83
Revenue
$33.77M
Gross profit
$33.77M
Operating income
-$91.81M
Net income
-$87.12M
EBIT
-$90.29M
EBITDA
-$79.73M
Free cash flow
-$98.92M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$2.66
Book value per share
$5.24
Revenue per share
$0.91
TBVPS
$7.33
Total assets
$272.28M
Total liabilities
$76.45M
Debt
$42.99M
Equity
$195.83M
Working capital
$178.42M
Debt to equity
0.22
Current ratio
6.36
Quick ratio
6.35
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
-236.1%
Gross margin
100%
Net margin
-258%
Operating margin
-271.9%
Return on assets
-27.8%
Return on equity
-38.8%
Return on invested capital
-31.5%
Return on capital employed
-37.8%
Return on sales
-267.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGX stock price
How has the Metagenomi stock price performed over time
Intraday
-1.31%
1 week
-3.83%
1 month
-14.72%
1 year
7.11%
YTD
-37.4%
QTD
-4.64%
Financial performance
How have Metagenomi's revenue and profit performed over time
Revenue
$33.77M
Gross profit
$33.77M
Operating income
-$91.81M
Net income
-$87.12M
Gross margin
100%
Net margin
-258%
The net margin has dropped by 92% year-on-year and by 50% since the previous quarter
Metagenomi's operating margin has shrunk by 72% YoY and by 40% QoQ
The company's gross profit fell by 40% YoY and by 25% QoQ
The revenue has declined by 40% year-on-year and by 25% since the previous quarter
Price vs fundamentals
How does MGX's price correlate with its fundamentals
Growth
What is Metagenomi's growth rate over time
Valuation
What is Metagenomi stock price valuation
P/E
N/A
P/B
0.43
P/S
2.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.83
Metagenomi's EPS has soared by 82% YoY but it has decreased by 12% from the previous quarter
The equity has declined by 27% year-on-year and by 8% since the previous quarter
The P/B is 8% higher than the last 4 quarters average of 0.4
MGX's price to sales (P/S) is 56% higher than its last 4 quarters average of 1.6
The revenue has declined by 40% year-on-year and by 25% since the previous quarter
Efficiency
How efficient is Metagenomi business performance
Metagenomi's ROS has plunged by 104% YoY and by 45% from the previous quarter
Metagenomi's ROE has soared by 62% YoY but it has decreased by 21% from the previous quarter
MGX's ROA is down by 44% YoY and by 22% QoQ
The ROIC has contracted by 15% from the previous quarter and by 14% YoY
Dividends
What is MGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGX.
Financial health
How did Metagenomi financials performed over time
Metagenomi's total liabilities has decreased by 34% YoY and by 10% QoQ
The total assets has contracted by 29% YoY and by 9% from the previous quarter
The debt is 78% smaller than the equity
The equity has declined by 27% year-on-year and by 8% since the previous quarter
The company's debt to equity rose by 22% YoY and by 4.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.